CIK 0001636651 · Non-accelerated filer<br>Smaller reporting company
Ovid Therapeutics Inc.
Sign in to watch- Ticker
- OVID
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 465270895
- Phone
- 212-776-4381
- Business address
- 441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10001
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-06-14 | Duncan Barbara Gayle Director | Grant or award · Stock Option (Right to Buy) | +11,627 | 11,627 | ||
| 2017-05-10 | Werber Yaron CBO, CFO, Sec. and Treas. | Grant or award · Employee Stock Option (Right to Buy) | +93,022 | 93,022 | ||
| 2017-05-10 | LEVIN JEREMY M CEO | Conversion | +400,150 | 4,586,195 | ||
| 2017-05-10 | LEVIN JEREMY M CEO | Conversion | +35,461 | 35,461 | ||
| 2017-05-10 | LEVIN JEREMY M CEO | Conversion · Series A Preferred Stock | −400,150 | 0 | ||
| 2017-05-10 | LEVIN JEREMY M CEO | Conversion · Series B Preferred Stock | −35,461 | 0 | ||
| 2017-05-10 | During Matthew President and CSO | Conversion | +28,245 | 4,307,314 | ||
| 2017-05-10 | During Matthew President and CSO | Conversion · Series A Preferred Stock | −28,245 | 0 | ||
| 2017-05-10 | Daly Timothy VP, Finance & Corp. Controller | Grant or award · Employee Stock Option (Right to Buy) | +46,510 | 46,510 |
Page 10 of 10 · 189 trades